

Novel leads and drugs for vector borne diseases: Targets and off targets (toxicity and ecotoxicity) and mechanism of action”

Thursday 19th and Friday 20th September 2024

National Hellenic Research Foundation, Athens, Greece

Thursday 19th September 2024	
08:30	Arrival & registration
09:00	Welcome
Session 1: Targets and Mechanism of Action Studies for Vector Borne Diseases (Chairing:.....)	
09:15	“Innovative approaches to target trypanothione reductase an essential enzyme for the survival of trypanosomatids in the host” Andrea Ilari, Università Sapienza, Italy
09:35	“Cyclic AMP signaling and nucleoside activated Protein Kinase A in Trypanosoma and Leishmania: genetic target validation and structure-guided inhibitor design” Michael Boshart, University of Munich (LMU), Germany
09:55	“Chemical tools to decipher the modes of action of antiplasmodial redox-active 3-benzylmenadiones” Elisabeth Davioud-Charvet, CNRS-Université de Strasbourg-Université Haute-Alsace, France
10:15	“Unravelling the mechanism of action of highly potent Pteridine Reductase 1 inhibitors: new insights into dual targeting of PTR1 and DHFR Nuno Santarém, Universidade do Porto, Portugal.
10:35	Coffee Break
11:05	Promoters: Cecilia Pozzi, Ulrike Wittig and the Team OHD1 - Target database project: the BioTarget DataBase (BioT-DB) Round table discussion: Structural biology approaches to understand and fight VBDs.
Session 2: Novel leads and drugs for Vector Borne Diseases (Chairing:)	
12:00	“Phenotypic and target-based screening of nucleoside analogues as antitrypanosomal agents”

	<i>Ewout Van de Velde, Ghent University, Belgium. Recipient of the "Best presentation on vector-borne diseases" from the COST action (CA21111) at the Paul Ehrlich meeting held in Rome on June 2024.</i>
12:20	<i>"Specialized pro-resolving mediators as leads for resolution pharmacology targeting vector borne diseases." Trond Vidar Hansen, University of Oslo, Norway</i>
12:40	<i>"Robenidine Derivatives As Potential Antischistosomal Drug Candidates" Christian N. Lotz, University of Basel, Switzerland</i>
13:00	<i>Break-Refreshments</i>
14:00	<i>"Synthesis and Anti-Parasitic Evaluation of Fused N,S-Heterocyclic Derivatives" Maria João Ribeiro Queiroz , Universidade of Minho, Portugal</i>
14:20	<i>"Discovery and preliminary preclinical in vivo evaluation of a dicationic candidate for the oral treatment of leishmaniasis" Christophe Dardonville, Medicinal Chemistry Institute, CSIC. C. Madrid, Spain.</i>
14:40	<i>"Arnica tincture is effective against cutaneous Leishmaniasis in human patients: A novel drug for this vector borne disease without toxic or ecotoxicological impact" Thomas J. Schmidt, University of Münster, Germany</i>
15:00	<i>Drug Discovery and Development for Human and Animal African Trypanosomiasis: A Comprehensive Database of Natural Compounds with Anti-trypanosomal Activity" Laura Bertarini, University of Modena and Reggio Emilia, Italy</i>
15:20	Promoters: Jose Maria Alunda and Anabela Cordeiro da Silva and the Team OHD3 project: Transition from in vitro to in vivo evaluation: recommendations for obtaining high-quality leads against kinetoplastids and round table discussion.
16:00	<i>Coffee break</i>
16:30- 18:40	<i>Poster Presentations. Oral presentations of posters (3 slides-7min). In the case of multiple accepted posters by the same presenting author they should select one to present.</i>
20:30	<i>Dinner</i>

Friday 20th September

Session 3: Medicinal chemistry and One Health principle integration: expanding the concepts of selectivity in drug discovery
(Chairing:)

09:00 National and Kapodistrian University of Athens, Greece
University of Athens, Greece

09:20	<i>CLOUDPHARM</i> <i>Title to be announced</i> <i>Athens, Greece</i>
09:40	<i>Antonio Brogi</i> <i>Title to be announced</i> <i>University of Pisa, Italy</i>
10:00	<i>“Optimizing Trypanothione Reductase Inhibitors for Leishmania Treatment: A Multiparametric Prediction Approach to Enhance Solubility and Biodegradability”</i> <i>Sandra Gemma, University of Siena, Italy</i>
10:20	<i>“Development of NMT-A004-loaded biodegradable nanocarriers”</i> <i>Theano Fotopoulou, National Hellenic Research Foundation, Greece</i>
10:40	Coffee Break
11:10	<i>“One Health Approach in Drug Discovery for Leishmaniasis by Targeting Calpain cys-protease”</i> <i>Daniele Aiello, University of Modena and Reggio Emilia, Italy</i>
11:30	<i>“Innovative Therapeutic Strategies for Vector-Borne Diseases: Exploring Novel Drug Targets and Addressing Off-Target Toxicity”</i> <i>Lori Doko, University of natural sciences and biological sciences, Albania</i>
11:50	<i>“Bioethical and human security approaches on evolution of drugs for vector borne diseases</i> <i>Serghei Sprincean, Moldova State University, Moldova</i>
12:10	Promoters: Sandra Gemma and Gulsah Bayraktar and the Team OHD2 – Compound Database project: Antiparasitic drug discovery and emerging scaffolds with predictive low environmental impact. Round table discussion
13:00	Break-Refreshments
14:00	<i>COST CA21111meeting (Planning Action activities and YRI)</i>
17:00	<i>Closing remarks</i>